바이오인

Biofluid Biopsies Utilizing Circulating Biomarkers

Minimally Invasive Technique Could Replace Tumor Tissue Collection and Advance Targeted Therapies

Enal Razvi, Ph.D

Currently circulating tumor cells are prognostic biomarkers for a few cancer classes.

The of this GEN Market & Tech Analysis report is to assess the promise of biofluid biopsies.

● The field of biofluid-based biopsies for cancer and other disease classes is ing to expand driven in large part by the promise of “minimally-invasive diagnostics”
● Circulating Biomarkers provide the backbone for biofluid biopsies as the former enable the capture of relevant analytes (biomarkers) and their interrogation ex vivo
● Various classes of Circulating Biomarkers are currently in play:
- Circulating Tumor Cells (CTCs)
- Circulating Nucleic Acids - circulating DNA and circulating RNA
- Circulating Extracellular Vesicles (EVs)

● We believe strongly that the field of biofluid biopsies will converge with point-of-care diagnostics as similar drivers are at play in both of these fields

● There is strong engagement by companies seeking entry into the circulating biomarkers and ultimately biofluid biopsies space

...................(계속)

☞ 자세한 내용은 내용바로가기 또는 첨부파일을 이용하시기 바랍니다.